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Abstract
Background & aims—Non-invasive biomarkers are needed for monitoring changes in liver 
histology in patients with non-alcoholic steatohepatitis (NASH). Obeticholic acid (OCA) was 
shown to improve fibrosis in patients with NASH in the FLINT trial; a post hoc analysis of these 
data was performed to determine the relationship between 3 non-invasive fibrosis markers and 
liver fibrosis improvement.
Methods—In the Phase 2b FLINT trial, patients were randomised (1:1) to receive 25 mg OCA or 
placebo once daily for 72 weeks. Aspartate aminotransferase:platelet ratio index (APRI), fibrosis-4 
(FIB-4) index, and non-alcoholic fatty liver disease fibrosis score (NFS) were evaluated in serum 
at baseline and weeks 24, 48, 72, and 96. Liver biopsies were obtained at baseline and 72 weeks.
Results—In patients with fibrosis improvement at week 24, scores were reduced by a median of 
34% for APRI, 10% for FIB-4, and 4% for NFS. Reductions in APRI (p=0.015) and FIB-4 
(p=0.036), but not NFS (p=0.201) at week 24, significantly correlated with ≥1-stage improvement 
in histologic fibrosis at week 72. Reductions in APRI at week 72 were significantly correlated 
with fibrosis improvement at week 72 (p=0.012). Patients receiving OCA had significant 
reductions in all markers compared with patients receiving placebo at week 72 [APRI and FIB-4 
(p<0.0001); NFS (p<0.05)].
Conclusions—Readily available non-invasive markers may predict improvement in liver fibrosis 
in patients with NASH. Upon external confirmation and further refinement in larger populations, 
these markers may serve as surrogate end points in NASH clinical trials.
Keywords
Non-alcoholic steatohepatitis; biomarkers; non-invasive; fibrosis
Introduction
Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver 
disease (NAFLD) that can progress to cirrhosis and end-stage liver disease.1,2 The disease 
increasingly contributes to the need for liver transplantation and to the development of 
hepatocellular carcinoma.1,2 Liver-related morbidity and mortality in patients with NASH 
are largely related to fibrotic remodelling of the liver into cirrhosis,3–5 A key objective of 
drug development for NASH is to reduce both the histologic severity of NASH and the 
fibrosis stage.6
Chalasani et al. Page 2
Liver Int. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Obeticholic acid (OCA) is a selective and potent farnesoid X receptor agonist previously 
shown to improve insulin resistance in a Phase 2 study of patients with NAFLD and type 2 
diabetes mellitus.7 In the Phase 2B Farnesoid X Receptor Ligand Obeticholic Acid in Non-
alcoholic Steatohepatitis Treatment (FLINT) trial, histologic features, including fibrosis 
stage, improved in significantly more patients treated with OCA than with placebo.8
A liver biopsy with histologic examination is the gold standard for the assessment of hepatic 
fibrosis.9 Liver biopsy is a potentially painful and costly procedure that is invasive, but 
rarely life-threatening.9,10 In some clinical trials or follow-up schedules, potential concerns 
are exacerbated by the need for serial biopsy evaluations.11 Histologic evaluation is 
subjective and therefore vulnerable to intraobserver and interobserver variability.9,12 
Furthermore, length and core diameter can affect the biopsy reading.11 Biopsies may not be 
broadly appropriate across patients with a risk of NASH given the ~30% prevalence rate of 
NAFLD in the general population and paucity of healthcare professionals trained in 
performing liver biopsies.13
To address the shortcomings of liver biopsies, several non-invasive laboratory-based tools 
have been developed for the assessment of hepatic fibrosis in patients with NASH. Such 
biomarkers can potentially be used to identify the current stage of fibrosis or fibrogenic 
activity or to predict the future trajectory of fibrosis change during the course of the disease 
or in response to specific antifibrotic interventions. Most of the literature has not focused on 
the specific context of use for the biomarkers under consideration. A key unanswered 
question is whether these laboratory-based tools can identify improvement in fibrosis once 
treatment is initiated. This study was therefore performed to obtain early proof-of-concept 
data on the ability of these laboratory tools to identify improvements in fibrosis following 
intervention in the context of the FLINT trial.
Three commonly used panels were tested; the aspartate aminotransferase:platelet ratio index 
(APRI), fibrosis-4 (FIB-4) index, and non-alcoholic fatty liver disease fibrosis score (NFS) 
involve routine laboratory measures and have had better predictive value than other non-
invasive serum markers for identifying advanced fibrosis and in excluding the presence of 
fibrosis.14–18 However, these assessments may be less sensitive in detecting changes in the 
intermediate stages of fibrosis.9 A meta-analysis showed better diagnostic performance of 
FIB-4 and NFS than APRI in NAFLD.19
The enhanced liver fibrosis test has been shown to identify advanced fibrosis, but more 
studies are required to further assess its clinical role.20,21 The objectives of the current post 
hoc analysis of the FLINT trial were to evaluate changes from baseline in APRI, FIB-4 
index, and NFS over time, examine their relationship with fibrosis improvement or 
worsening at week 72, and assess whether changes in these markers predict alteration in 
fibrosis stage at the end of treatment. This analysis will indicate whether early results with 
these three non-invasive markers predict later improvement in hepatic lobular fibrosis and 
treatment responsiveness to OCA.
Chalasani et al. Page 3
Liver Int. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Materials and methods
Study design and patients
This post hoc analysis used data from the FLINT trial (ClinicalTrials.gov identifier: 
NCT01265498), a multicentre, prospective, randomised, placebo-controlled, double-blind 
Phase 2b study of the efficacy and safety of OCA for the treatment of NASH. The primary 
results have been published previously, along with a complete description of the trial design 
and patient disposition.8 The full protocol is available at http://jhuccs1.us/nash/open/
protocols/FLINT/FLINTdocs.htm.
Briefly, enrolled patients had biopsy-proven NASH with high disease activity, defined as a 
non-alcoholic fatty liver disease activity score (NAS) ≥4. Biopsy specimens were at least 0.5 
cm in length. Clinical and laboratory assessments were performed at baseline and at 3-
month intervals until the end of treatment (EOT) at 72 weeks. Patients underwent an EOT 
liver biopsy to assess the efficacy of OCA. Study treatments (i.e. OCA and placebo) were 
then discontinued, and a 6-month follow-up period was used to determine the durability of 
clinical and laboratory changes associated with OCA treatment. APRI, FIB-4 index, and 
NFS were determined using platelet count and levels of albumin, alanine aminotransferase 
(ALT), and aspartate aminotransferase (AST) obtained at baseline and weeks 24, 48, 72, and 
96. The pathology committee of the NASH Clinical Research Network (CRN) performed 
masked liver histology assessments as described previously.8
Baseline and EOT histologic data for the 200 patients who had completed the EOT biopsy at 
the time of a prespecified interim assessment indicated significant effects of OCA on all 
components of NASH. The independent data safety and monitoring board determined that 
imposing the risks of a research-related biopsy and continuing treatment exposure were 
unnecessary for the remaining patients because their liver biopsy results were not anticipated 
to substantially alter overall trial results. Of patients who reached the 72-week EOT time 
point, 91% underwent an EOT liver biopsy.
Non-invasive fibrosis markers
The following non-invasive markers of fibrosis were examined in sera at baseline and weeks 
24, 48, 72, and 96 as follows14,15,17,18:
APRI = {[AST (U/L)/AST (ULN)/platelets (109/L)]} × 100
FIB-4 = age (y) × AST (U/L)/[platelets (109/L) × ALT (U/L)]½
NFS = −1.675 + 0.037 × age (y) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes 
(yes=1, no=0) + 0.99 × AST/ALT ratio – 0.013 platelets (109/L) – 0.66 × albumin 
(g/dL)
where ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body 
mass index; IFG, impaired fasting glucose; ULN, upper limit of normal.
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Statistical analysis
Analyses were conducted using primarily the completer population, defined as all patients 
who were randomised, received treatment, and had available biopsy results for both baseline 
and 72 weeks.
Continuous variables for patient baseline characteristics, including APRI, FIB-4 index, and 
NFS, were compared between the OCA and placebo groups in the completer population via 
analysis of covariance (ANCOVA) with stratification for study site and diabetes status. 
Diabetes status was compared between treatment groups using the Cochran-Mantel-
Haenszel chi-square test with stratification for study site. Mean and 95% confidence 
intervals (CIs) for each marker at each visit and least squares (LS) means and 95% CIs for 
change from baseline at each visit were plotted by treatment group. Treatment effects were 
compared using ANCOVA models, controlling for baseline outcome value. To demonstrate 
reproducibility of results, a similar analysis was conducted for the intent-to-treat (ITT) 
population, defined as all patients who were randomised and received treatment. Mean and 
95% CI for each marker at each visit were also plotted by fibrosis stage at baseline for the 
completer population. Wilcoxon rank sum analysis was used to evaluate the association 
between the median percentage change from baseline to week 24 in scores for each marker 
among patients with fibrosis improvement noted on the EOT biopsy and an improvement in 
histologic fibrosis of ≥1 stage at week 72. A logistic regression model including the entire 
completer population was used to evaluate early (i.e. 24-week) changes in the markers as 
predictors of improvement in histologic fibrosis at 72 weeks. A similar analysis was 
repeated for the median percentage change from baseline to week 72 in scores for each 
marker with fibrosis improvement, and a logistic regression model including the entire 
completer population was used to evaluate changes in markers at 72 weeks as predictors of 
histologic improvement. Patients with missing data at a time point were not included in the 
analysis for that time point. For each marker, a receiver operating characteristic (ROC) curve 
of sensitivity versus specificity of predicting a histologic response was plotted, and the area 
under the ROC curve (AUROC), 95% CI, negative predictive values (NPVs), and positive 
predictive values (PPVs) were calculated.
All post hoc analyses were conducted using SAS® 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
In the FLINT trial, 283 patients were randomly assigned to receive OCA (n=141) or placebo 
(n=142) and comprised the ITT population (supplemental figure 1).8 Two hundred 
comprised the completer population with baseline and EOT biopsies (OCA, n=102; placebo, 
n=98).8 Baseline characteristics, including APRI, FIB-4 index, and NFS, were similar 
between the OCA and placebo groups (table 1).8 The mean (min, max) length of biopsy 
specimens for patients was 2.1 cm (0.5, 6.1 cm) at baseline and 1.8 cm (0.5, 4.8 cm) at 72 
weeks.
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Changes in markers over time (completer and ITT populations)
In the completer population, statistically significant differences in the change from baseline 
were seen between the OCA and placebo groups at 24, 48, and 72 weeks for APRI and 
FIB-4 scores (figure 1). APRI, FIB-4 index, and NFS decreased over time with OCA 
treatment and increased after treatment discontinuation (figure 1). At 24, 48, and 72 weeks, 
mean APRI scores in the OCA group were below 0.5, indicating a low probability of 
advanced fibrosis (figure 1A). Similarly, mean FIB-4 scores in the OCA group were below 
1.3 at 48 and 72 weeks (figure 1B). See supplemental table 1 for results with additional 
cutoffs.
Consistent with the completer population, the ITT population had significant differences in 
the change from baseline between the OCA and placebo groups at 24, 48, and 72 weeks for 
APRI and FIB-4 scores (supplemental figure 2). The ITT population also had significant 
differences after treatment discontinuation for FIB-4 score and at 72 weeks for NFS score 
(supplemental figure 2).
Patients grouped by baseline fibrosis stage showed changes in APRI and FIB-4 scores over 
time in the OCA group across baseline fibrosis stages 1 through 3, with higher baseline 
fibrosis stages demonstrating more pronounced improvements (figure 2). No clear trends 
were observed for changes in NFS over time relating to baseline fibrosis stage in either OCA 
or placebo group (figure 2C).
With the fastest rate of change in APRI and FIB-4 index scores occurring between baseline 
and week 24, week 24 was the focus of analyses to evaluate early changes in the markers as 
predictors of later histologic improvement in fibrosis at week 72.
Changes in markers as predictors of histologic improvement in fibrosis (completer 
population)
Generally, APRI, FIB-4 index, and NFS reductions were more pronounced over time in 
patients with an improvement in fibrosis ≥1 histologic stages at 72 weeks than in those 
without improvement (figure 3).
In patients with fibrosis improvement, median scores were reduced at 24 weeks by 34% for 
APRI and 10% for the FIB-4 index. These median reductions in scores at 24 weeks were 
significantly associated with an improvement of ≥1 stage in histologic fibrosis at 72 weeks 
(Wilcoxon rank sum analysis; APRI, p=0.015; FIB-4, p=0.036; figure 3A-B). There was no 
association between the median percentage change from baseline to 24 weeks in NFS (4%) 
and the improvement in fibrosis at 72 weeks (p=0.201; figure 3C). AUROC analyses (figure 
4) for predicting histologic improvement in fibrosis at 72 weeks showed a numerically lower 
AUROC for NFS (0.65, 95% CI: 0.56–0.73) than for APRI (0.72, 95% CI: 0.65–0.80) or 
FIB-4 score (0.68, 95% CI: 0.60–0.76) at 24 weeks (figure 4, table 2), and PPVs and NPVs 
were also lower (table 2). The probability equation for predicting histologic improvement in 
fibrosis for each measure is shown in table 2.
The median percentage score reduction at 72 weeks was significantly associated with an 
improvement of ≥1 stage in fibrosis at 72 weeks only for APRI (p=0.012; figure 3A). For 
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both FIB-4 index and NFS, median percentage score changes from baseline to 72 weeks 
were not significantly associated with an improvement in fibrosis at 72 weeks (FIB-4, 
p=0.497; NFS, p=0.164; figures 3B and 3C). The AUROC values were higher for APRI 
(0.73) than for FIB-4 (0.67) and NFS (0.66) at 72 weeks; the PPV was highest for APRI, and 
the NPV was highest for NFS (supplemental figure 3, supplemental table 2).
Changes in biomarker components over time (completer population)
ALT and AST levels decreased from baseline to 24, 48, and 72 weeks with OCA treatment 
and increased during the off-treatment period, whereas the AST/ALT ratio and platelet count 
increased within the normal range with OCA and decreased after treatment discontinuation 
(supplemental figure 4). Increases in the AST/ALT ratio in the OCA group were driven by 
non-proportional reductions in AST and ALT levels with OCA treatment, rather than rising 
AST or ALT level. These changes were significantly different between the OCA group 
(during treatment) and the placebo group (supplemental figure 4). Serum albumin was 
significantly lower in the OCA than the placebo group at 24 and 72 weeks (supplemental 
figure 4).
Changes in markers over time in patients with fibrosis worsening (completer population)
Changes in APRI, FIB-4 index, and NFS scores were minimal for the 51 patients who 
demonstrated a worsening of fibrosis over time (supplemental figure 5).
Discussion
Results of this post hoc analysis provide proof of concept that longitudinal changes in non-
invasive measures of fibrosis correlate with improvements in histologic fibrosis. 
Improvements from baseline in APRI and FIB-4 scores occurred with OCA treatment 
regardless of baseline disease stage, with greater benefits at higher baseline fibrosis stages. 
Decreases from baseline in APRI, FIB-4 index, and NFS were significantly more 
pronounced with OCA than with placebo, which was observed as early as 24 weeks and was 
sustained over the course of treatment for APRI and FIB-4 scores. APRI and FIB-4 scores 
were more sensitive than NFS in predicting later fibrosis stage improvements.
Results from a meta-analysis showed better diagnostic performance of FIB-4 and NFS than 
APRI in NAFLD.19 Given that OCA consistently improved APRI in this study, further 
validation in future studies will help to validate marker sensitivity for predicting fibrosis 
improvements.
The lower overall sensitivity of the NFS may be associated with its AST/ALT ratio 
component. Small increases in the AST/ALT ratio were significant and sustained over time 
on the basis of non-proportional reductions in AST and ALT levels. The individual AST and 
ALT improvements were inaccurately reflected by the AST/ALT ratio increases, suggesting 
that the NFS may have underestimated the effects of OCA treatment on fibrosis. An 
additional finding was the lack of sensitivity to worsening fibrosis for all of the non-invasive 
markers evaluated. Patients who experienced histologic worsening in fibrosis had almost no 
change from baseline in APRI, FIB-4 index, or NFS. This observation could be explained by 
a potential sampling artefact that led to an overestimate of the degree of liver fibrosis on the 
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EOT biopsy compared with baseline.22 Alternatively, the risk of a type II error for 
identifying worsening fibrosis with these tests is possible.
Limitations of this evaluation include the need to interpret post hoc and subgroup analyses 
of clinical studies with caution until further validation.23 In addition, the limited sampling 
frequency in the FLINT trial for both laboratory biomarkers (i.e. once every 24 weeks) and 
histologic evaluations (i.e. at baseline and 72 weeks) precluded the ability to assess the time 
to effect of OCA on these outcomes and the predictive value of APRI, FIB-4 index, and NFS 
at time points earlier than 24 weeks. Moreover, the relatively wide CIs for the AUROC 
findings in this analysis may suggest the need to investigate the predictive value of 
additional biomarkers.
Several previous studies evaluated longitudinal changes in non-invasive measures of fibrosis 
and associations with histologic or clinical outcomes24–30; however, limited reports have 
paired these assessments with liver biopsy evaluations.25,27,28,30 Among the serum markers 
currently available for non-invasive evaluation of fibrosis, APRI, FIB-4 index, and NFS have 
been used and validated most extensively.9,31 Advantages of APRI and FIB-4 scores over 
patented non-invasive tests include a lack of additional costs, ease of calculation, and wide 
availability.9 However, all of the serum markers are less well validated across the spectrum 
of NAFLD than in hepatitis C virus, hepatitis B virus, or human immunodeficiency virus/
hepatitis C virus co-infection.9 Results of the primary analysis from the Phase 2b FLINT 
trial (N=283) in patients with NASH showed that OCA-related improvements in the more 
commonly used APRI and FIB-4 scores may be correlated with histologic treatment benefits 
such as improvements in fibrosis (OCA 35% and placebo 19%).8 With further validation, 
these findings may improve clinicians’ ability to decide whether to continue OCA therapy, 
thereby mitigating the potential risks, complications, and logistical issues associated with 
liver biopsy.
Although these data are insufficient to draw definitive conclusions, they provide proof of 
concept that fibrosis improvement is associated with improvement in these indices and 
provide a rationale for larger prospective studies to further validate their use for 
identification of treatment response and to develop “stopping rules.” Evaluation of the 
effects of OCA on these markers in patients with NASH from the REGENERATE trial 
(ClinicalTrials.gov identifier: NCT02548351) is currently under way. These results also 
support the need for more accurate biomarkers that can identify both improvement and 
worsening of fibrosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations (in order of appearance):
NASH non-alcoholic steatohepatitis
NAFLD non-alcoholic fatty liver disease
OBA obeticholic acid
FLINT Farnesoid X Receptor Ligand Obeticholic Acid in Non-alcoholic 
Steatohepatitis Treatment
APRI aminotransferase:platelet ratio index
FIB-4 fibrosis-4
NFS non-alcoholic fatty liver disease fibrosis score
NAS non-alcoholic fatty liver disease activity score
EOT end of treatment
ALT alanine aminotransferase
AST aspartate aminotransferase
CRN Clinical Research Network
BMI body mass index
IFG impaired fasting glucose
ULN upper limit of normal
ANCOVA analysis of covariance
CI confidence interval
LS least squares
ITT intent-to-treat
ROC receiver operating characteristic
AUROC area under the ROC curve
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Key points:
• Liver biopsy remains the gold standard for assessing fibrosis status, but non-
invasive technologies may improve the standard of care for patients with liver 
disease
• In FLINT, OCA treatment resulted in histologic improvement in fibrosis
• In the present post hoc analysis of FLINT, the histologic benefits of OCA 
treatment appeared to correlate with improvements in APRI and FIB-4 scores
• These results suggest the potential utility of non-invasive measures in 
predicting treatment response with OCA
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Figure 1. 
Mean and mean change for APRI, FIB-4, and NFS scores over time: Completer population.
**p<0.01; ***p<0.0001. p values were calculated using ANCOVA models, controlling for 
baseline value of the outcome. Patients with missing data at a specific time point were not 
included in the analysis for that time point.
The completer population was defined as all patients who were randomly assigned, received 
treatment and had available biopsy results for both baseline and 72 weeks. ANCOVA, 
analysis of covariance; APRI, aspartate aminotransferase:platelet ratio index; CI, confidence 
Chalasani et al. Page 13
Liver Int. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interval; FIB-4, fibrosis-4; LS, least squares; OCA, obeticholic acid; NFS, non-alcoholic 
fatty liver disease fibrosis score.
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Figure 2. 
Mean change from baseline to Week 72 for APRI, FIB-4, and NFS by baseline fibrosis stage 
for OCA (teal) and placebo (grey): Completer population.
Patients with missing data at a specific time point were not included in the analysis for that 
time point.
The completer population was defined as all patients who were randomly assigned, received 
treatment and had available biopsy results for both baseline and 72 weeks.
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APRI, aspartate aminotransferase:platelet ratio index; CI, confidence interval; FIB-4, 
fibrosis-4; OCA, obeticholic acid; NFS, non-alcoholic fatty liver disease fibrosis score.
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Figure 3: 
Median percentage change from baseline in APRI, FIB-4, and NFS by improvement in 
histologic stage at 72 weeks: Completer population.
Patients with missing data at a specific time point were not included in the analysis for that 
time point.
The completer population was defined as all patients who were randomly assigned, received 
treatment and had available biopsy results for both baseline and 72 weeks.
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APRI, aspartate aminotransferase:platelet ratio index; FIB-4, fibrosis-4; NFS, non-alcoholic 
fatty liver disease fibrosis score.
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Figure 4: 
ROC curve for APRI, FIB-4, and NFS at 24 weeks as predictors of histologic improvement 
in fibrosis at week 72 showing sensitivity and specificity: Completer population.
The completer population was defined as all patients who were randomly assigned, received 
treatment and had available biopsy results for both baseline and 72 weeks.
APRI, aspartate aminotransferase:platelet ratio index; FIB-4, fibrosis-4; NFS, non-alcoholic 
fatty liver disease fibrosis score; ROC, receiver operator characteristic.
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Table 1:
Baseline characteristics: Completer population
Parameter OCA 25 mg(n=102)
Placebo
(n=98)
Age (y) 52 (11) 50 (12)
BMI (kg/m2) 35 (6)a 34 (6)
Diabetes (%) 53 54
AST (U/L) 64 (39) 56 (31)
ALT (U/L) 82 (48) 82 (49)
ALP (U/L) 82 (28) 81 (25)
Triglycerides (mmol/L) 2.4 (3.5) 2.1 (2.0)
Platelets (109/L) 241 (60) 242 (65)
Albumin (g/L) 43 (4) 43 (4)
APRI 0.7 (0.5) 0.6 (0.4)
FIB-4 1.6 (0.8) 1.4 (0.7)
NFS
–1.0 (1.4)a –1.3 (1.3)
Data are mean (SD) unless otherwise indicated.
a
n=101.
The completer population was defined as all patients who were randomly assigned and received treatment and who had available biopsy results for 
both baseline and 72 weeks.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, aspartate aminotransferase:platelet ratio index; AST, aspartate aminotransferase; 
BMI, body mass index; FIB-4, fibrosis-4; OCA, obeticholic acid; NFS, non-alcoholic fatty liver disease fibrosis score; SD, standard deviation.
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Table 2:
Performance characteristics of non-invasive measures for the prediction of fibrosis improvement at 24 weeks: 
Completer population
Score Cut-
off
AUROC
(95% CI) NPV PPV Probability Equation
APRI 0.23 0.72(0.65, 0.80) 89.9% 43.4%
−1.25 + 0.71 x baseline fibrosis stage
− 3.00 x baseline APRI − 2.74 *
change in APRI at week 24 + 0.59 x
(1 if OCA, 0 if PBO)
FIB-4 0.20 0.68(0.60, 0.76) 91.0% 38.3%
−1.68 + 0.68 x baseline fibrosis stage
− 0.77 x baseline FIB-4 − 0.78 *
change in FIB-4 at week 24 + 0.81 x
(1 if OCA, 0 if PBO)
NFS 0.20 0.65(0.56, 0.73) 89.1% 36.0%
−2.75 + 0.60 x baseline fibrosis stage
− 0.19 x baseline NFS − 0.49 *
change in NFS at week 24 + 0.84 x
(1 if OCA, 0 if PBO)
The completer population was defined as all patients who were randomly assigned and received treatment and who had available biopsy results for 
both baseline and 72 weeks. The NPV and PPV were calculated based on 195 patients for APRI and FIB-4 and 191 patients for NFS.
APRI, aspartate aminotransferase:platelet ratio index; AUROC, area under the receiver operator characteristic curve; CI, confidence interval; FIB-4, 
fibrosis-4; NFS, non-alcoholic fatty liver disease fibrosis score; NPV, negative predictive value; PBO, placebo; OCA, obeticholic acid; PPV, 
positive predictive value.
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